The Pharmacy Times® Hepatitis Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of distinct diseases that cause inflammation of the liver, including hepatitis A, B, C, and D.
July 7th 2025
Y-90 resin microspheres offer a new option for patients with liver cancer for the treatment of unresectable hepatocellular carcinoma.
FDA Approves Viekira Pak for Treatment of Hepatitis C Virus
December 19th 2014The FDA today approved ombitasvir, paritaprevir, and ritonavir tablets copackaged with dasabuvir tablets to treat individuals with chronic hepatitis C virus genotype 1 infection, including patients with cirrhosis.
Read More
The CVS Health Research Institute today released a first look at the comparative utilization of two new hepatitis C treatments in the weeks following their respective launches. The analysis shows an increase in the number of eligible hepatitis C patients being treated following the October launch of Harvoni®, the newest hepatitis C treatment.
Read More